Ceftiofur Tazobactam 1125 mg injection in Veterinary PCD Franchise

Product Description

Ceftiofur sodium has demonstrated excellentin vitroandin vivoactivity againstMannheimia haemolyticaandPasteurella multocida, two of the major pathogenic organisms associated with bovine respiratory disease (pneumonia, shipping fever). This drug has also demonstrated excellentin vitroandin vivoactivity againstHistophilus somni (Haemophilus somnus)andin vitroactivity againstCorynebacterium pyogenes, two other bacterial pathogens associated with bovine respiratory disease (BRD). Ceftiofur has demonstratedin vivoandin vitroactivity againstFusobacterium necrophorumandBacteroides melaninogenicus, two of the major pathogenic anaerobic bacteria associated with acute bovine interdigital necrobacillosis (foot rot, pododermatitis). Ceftiofur has excellentin vitroactivity against Gram-negative pathogens such asActinobacillus pleuropneumoniae, Salmonella choleraesuis, Pasteurella multocidaand the Gram-positive pathogenStreptococcus suis, all of which singly or in combination can be associated with swine bacterial respiratory disease (swine bacterial pneumonia). Ceftiofur has also demonstrated excellentin vitroandin vivoactivity against respiratory pathogens of horses. The drug was very activein vitroagainstStreptococcus zooepidemicus, S. equi, Streptococcus spp.andPasteurella spp.isolated from patients with infections. Ceftiofur has demonstratedin vitroandin vivoactivity againstMannheimia haemolytica, the major pathogenic bacterium associated with ovine respiratory disease (pneumonia). Ceftiofur has also demonstratedin vivoandin vitroactivity against bacterial pathogens from dogs with urinary tract infections. Ceftiofur was more potent(in vitro)than other beta-lactam antibiotics against strains ofEscherichia coliandProteus mirabilisCeftiofur sodium has demonstrated excellentin vitroandin vivoactivity againstMannheimia haemolyticaandPasteurella multocida, two of the major pathogenic organisms associated with bovine respiratory disease (pneumonia, shipping fever). This drug has also demonstrated excellentin vitroandin vivoactivity againstHistophilus somni (Haemophilus somnus)andin vitroactivity againstCorynebacterium pyogenes, two other bacterial pathogens associated with bovine respiratory disease (BRD). Ceftiofur has demonstratedin vivoandin vitroactivity againstFusobacterium necrophorumandBacteroides melaninogenicus, two of the major pathogenic anaerobic bacteria associated with acute bovine interdigital necrobacillosis (foot rot, pododermatitis). Ceftiofur has excellentin vitroactivity against Gram-negative pathogens such asActinobacillus pleuropneumoniae, Salmonella choleraesuis, Pasteurella multocidaand the Gram-positive pathogenStreptococcus suis, all of which singly or in combination can be associated with swine bacterial respiratory disease (swine bacterial pneumonia). Ceftiofur has also demonstrated excellentin vitroandin vivoactivity against respiratory pathogens of horses. The drug was very activein vitroagainstStreptococcus zooepidemicus, S. equi, Streptococcus spp.andPasteurella spp.isolated from patients with infections. Ceftiofur has demonstratedin vitroandin vivoactivity againstMannheimia haemolytica, the major pathogenic bacterium associated with ovine respiratory disease (pneumonia). Ceftiofur has also demonstratedin vivoandin vitroactivity against bacterial pathogens from dogs with urinary tract infections. Ceftiofur was more potent(in vitro)than other beta-lactam antibiotics against strains ofEscherichia coliandProteus mirabilisCeftiofur sodium has demonstrated excellentin vitroandin vivoactivity againstMannheimia haemolyticaandPasteurella multocida, two of the major pathogenic organisms associated with bovine respiratory disease (pneumonia, shipping fever). This drug has also demonstrated excellentin vitroandin vivoactivity againstHistophilus somni (Haemophilus somnus)andin vitroactivity againstCorynebacterium pyogenes, two other bacterial pathogens associated with bovine respiratory disease (BRD). Ceftiofur has demonstratedin vivoandin vitroactivity againstFusobacterium necrophorumandBacteroides melaninogenicus, two of the major pathogenic anaerobic bacteria associated with acute bovine interdigital necrobacillosis (foot rot, pododermatitis). Ceftiofur has excellentin vitroactivity against Gram-negative pathogens such asActinobacillus pleuropneumoniae, Salmonella choleraesuis, Pasteurella multocidaand the Gram-positive pathogenStreptococcus suis, all of which singly or in combination can be associated with swine bacterial respiratory disease (swine bacterial pneumonia). Ceftiofur has also demonstrated excellentin vitroandin vivoactivity against respiratory pathogens of horses. The drug was very activein vitroagainstStreptococcus zooepidemicus, S. equi, Streptococcus spp.andPasteurella spp.isolated from patients with infections. Ceftiofur has demonstratedin vitroandin vivoactivity againstMannheimia haemolytica, the major pathogenic bacterium associated with ovine respiratory disease (pneumonia). Ceftiofur has also demonstratedin vivoandin vitroactivity against bacterial pathogens from dogs with urinary tract infections. Ceftiofur was more potent(in vitro)than other beta-lactam antibiotics against strains ofEscherichia coliandProteus mirabilis